South Korea’s Hanmi Opens Global Trials Of Monthly Dose GLP-1 Biosimilar
This article was originally published in PharmAsia News
Executive Summary
Hanmi hopes to differentiate its type 2 diabetes Byetta biosimilar with once-a-month administration.
You may also be interested in...
Lilly Bullish On Diabetes/Oncology Products; Analysts Skeptical
The Indianapolis-based big pharma touted the value of its late-stage pipeline at an analyst meeting on Oct. 3, particularly its diabetes and oncology franchises, even though they face tough competition and have encountered some setbacks.
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Dupixent Shines At ATS, But Experts Question Which Novel Biologic Physicians Will Choose
Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.